As reported on PharmaBiz, Amgen has announced encouraging topline results from a phase 3 clinical trial evaluating a subcutaneous formulation of Tepezza (teprotumumab-trbw) for adults
Most of us have heard of the fight-or-flight stress response. It becomes activated when we believe there is a chance we can outfight or outrun
Telomir Pharmaceuticals has taken a significant step forward in the development of a novel therapeutic agent for one of oncology’s most challenging cancers. As reported
I have battled several autoimmune and neurological conditions that are triggered by food and other factors for over 50 years. It took most of my
The traditional model of HIV care has long centered on one fundamental requirement: patients must take medication every single day, without fail. Yet this model
As reported by GlobeNewsWire, results from the Phase 3 VALOR trial evaluating brepocitinib in adults with dermatomyositis have been published in the New England Journal
Editor’s Note: Patient Worthy is pleased to share the final part in a series of excerpts by Dana Langston. Chapter 36: Holding the Line Knowing
For patients living with primary biliary cholangitis (PBC), a rare autoimmune liver disease, an often-overlooked symptom has plagued their existence, an intense, maddening internal itch
As reported on PharmaBiz, a novel treatment strategy combining dual immunotherapy, targeted therapy, and transarterial chemoembolization (TACE) has demonstrated meaningful clinical benefit for patients with
Editor’s Note: Patient Worthy is pleased to share part 4 of 5 in a series of excerpts written by Dana Langston. Part 7: Legacy &
When standard depression medications fail, patients face a devastating reality. Approximately one-third of people with major depressive disorder do not adequately respond to conventional antidepressants,
As reported on BioPharmaDive, Amgen has announced positive Phase 3 results for a subcutaneous version of its thyroid eye disease (TED) therapy Tepezza, suggesting the
Editor’s Note: Patient Worthy is proud to bring you part 3 of 5 in a series of excerpts written by Dana Langston. Part 3: The
Ollin Biosciences has announced important clinical trial results showing that OLN324, an investigational eye treatment, outperforms an existing therapy in treating two serious retinal diseases
As reported on Business Wire, Alkermes plc has initiated a global phase 3 clinical development program to evaluate alixorexton, an investigational oral therapy for people
Editor’s Note: This is the second part in a series of excerpts written by Dana Langston. Chapter 4: The Internal Shift We are living in
Multiple myeloma, a cancer of plasma cells in the bone marrow, has become an increasingly manageable disease over the past two decades, thanks to successive
As reported on FierceBioTech, Gilead Sciences has closed one of its midstage clinical studies evaluating an experimental HIV regimen, following ongoing safety concerns that prompted
Patient Experience Week is April 27th through May 1st- a moment to honor the human side of healthcare. Behind every scan, every diagnosis, every quiet conversation is a patient trusting us with their story, their fears, and their hope. It's not just about images on a screen or numbers on a chart. It's about listening first, explaining clearly, and treating each person with dignity so they feel seen, safe, and supported.
This week we celebrate the teams who turn clinical care into genious care- the doctors who slow down to answer questions, the nurses who hold a hand, the staff who remember a name. Great medicine is both science and compassion.
#HumanCenteredCare #PatientFirst #PatientWorthy
Osteogenesis Imperfecta FoundationNational Conference Community Call: Program Deep Dive is on Tuesday, May 12 at 7:00PM ET!
As part of the OIF National Conference Community Call Series, this community call will focus on providing an overview of events and sessions that will be available at the conference. Visit www.oif.org/confcall4 to register to attend.
EB Research PartnershipWhat if we could help train doctors to spot cancer in EB earlier?
For people living with EB, squamous cell carcinoma (SCC) is a common risk and early signs can be difficult to recognize.
Dr. Amy Paller and her team at Northwestern University are working to improve detection using artificial intelligence.
By creating privacy-safe, AI-generated images based on real patient data, this project builds side-by-side comparisons, one with cSCC, one without, to help clinicians spot subtle differences earlier.
The work also expands image data across a wider range of skin tones, helping make detection more accurate and equitable.
It’s a more precise way to train both technology and doctors, supporting earlier diagnosis and better decision-making.
🧬 EBRP recently funded this innovative project as part of our latest research cycle.
Read more about our awarded projects. → ebresearch.us-1.smartsimple.com/files/1557436/f169478/index.html
🦋 Fund research that moves faster. All donations go 100% to research, and currently are doubled. → give.ebresearch.org/campaign/774055/donate?utm_source=organic+social&utm_medium=facebook&utm_camp...
© Copyright 2024 Patient Worthy
Sign Up With a Patient Worthy Account and Share Your Rare Story
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
- OR -
Make a difference, share your experiences and get paid. Opt-in and join Patient Worthy's panel for paid opportunities such as surveys, market research, patient advisory panels and more.
